Best Supplements for Reduced Aspartate Aminotransferase Level
Ranked by research evidence. Compare 34 supplements across 57 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence10 studies
Across 10 studies, 6 reported beneficial effects of thistle (silymarin) on reducing aspartate aminotransferase (AST) levels, with 4 neutral findings and no harmful effects. Predominant effect sizes were mixed (small to large), with meta-analyses showing moderate-to-large reductions (SMDs ranging from -0.14 to -2.68). Effects were observed primarily in clinical populations, with a median study duration of 63 days (about 9 weeks), and a commonly reported dose was 420 mg/day of silymarin.
Dose: 420 mg/day - Moderate evidence5 studies
Across 5 studies primarily in clinical populations with NAFLD/MASLD, vitamin E shows a beneficial effect on reducing AST levels, with most studies reporting small effect sizes. Evidence is strongest at doses of 298-1000 IU/day, with effects typically observed at 8-12 weeks. 3 of 5 studies reported beneficial effects, though only 2 reached statistical significance.
Dose: 298-1000 IU/day - Moderate evidence4 studies
Across 4 studies, 3 reported beneficial effects of red grape-derived interventions (primarily grape seed extract) on reducing aspartate aminotransferase (AST) levels, with effect sizes ranging from small to moderate. Effects were observed in clinical populations with NAFLD and β-thalassemia at doses of 100 mg/day and 520 mg/day over 4–8 weeks. The evidence is moderate, with 3 statistically significant findings, but the small number of studies and narrow populations limit generalizability.
- ModerateThistleAcross 10 studies, 6 reported beneficial effects of thistle (silymarin) on reducing aspartate aminotransferase (AST) levels, with 4 neutral findings and no harmful effects. Predominant effect sizes were mixed (small to large), with meta-analyses showing moderate-to-large reductions (SMDs ranging from -0.14 to -2.68). Effects were observed primarily in clinical populations, with a median study duration of 63 days (about 9 weeks), and a commonly reported dose was 420 mg/day of silymarin. · Dose: 420 mg/day6 beneficial4 neutral10 studies
- ModerateVitamin EAcross 5 studies primarily in clinical populations with NAFLD/MASLD, vitamin E shows a beneficial effect on reducing AST levels, with most studies reporting small effect sizes. Evidence is strongest at doses of 298-1000 IU/day, with effects typically observed at 8-12 weeks. 3 of 5 studies reported beneficial effects, though only 2 reached statistical significance. · Dose: 298-1000 IU/day3 beneficial2 neutral5 studies
- ModerateRed GrapeAcross 4 studies, 3 reported beneficial effects of red grape-derived interventions (primarily grape seed extract) on reducing aspartate aminotransferase (AST) levels, with effect sizes ranging from small to moderate. Effects were observed in clinical populations with NAFLD and β-thalassemia at doses of 100 mg/day and 520 mg/day over 4–8 weeks. The evidence is moderate, with 3 statistically significant findings, but the small number of studies and narrow populations limit generalizability.3 beneficial1 neutral4 studies
- LowBlack CuminAcross 3 studies, 1 reported a beneficial small effect on reducing aspartate aminotransferase (AST), while 2 found no significant effect. The overall evidence is mixed, with a neutral predominant finding. The most studied dose range is broad (200–4600 mg/day) and the median study duration is 19 days.1 beneficial2 neutral3 studies